TB-500

Overview

TB-500 is a synthetic version of Thymosin Beta-4 (Tb4), a naturally occurring 43-amino acid peptide that is one of the most abundant intracellular proteins in mammalian cells. Thymosin Beta-4 was originally isolated from the thymus gland by Allan Goldstein and colleagues at the George Washington University in the 1960s, though it was later discovered to be expressed ubiquitously throughout the body and not limited to thymic tissue.

Tb4 is the primary G-actin sequestering peptide in eukaryotic cells, maintaining a reservoir of monomeric actin (G-actin) that can be rapidly mobilized for cytoskeletal reorganization. This fundamental role in actin dynamics gives Tb4 influence over virtually every process that depends on cellular motility and structural remodeling, including wound healing, angiogenesis, inflammation, and cardiac repair.

The synthetic form, TB-500, replicates the full 43-amino acid sequence of endogenous Tb4. It has been the subject of extensive research in wound healing, corneal repair, cardiac regeneration, and neurological recovery. RegeneRx Biopharmaceuticals advanced Tb4-based therapeutics through multiple clinical trials, including Phase II studies for dry eye syndrome and cardiac repair following myocardial infarction.

Mechanism of Action

TB-500 exerts its biological effects through multiple interconnected mechanisms centered on actin cytoskeleton regulation and downstream signaling pathways.

Actin Sequestration and Dynamics

The primary biochemical function of Tb4 is sequestering monomeric G-actin in a 1:1 complex, preventing its spontaneous polymerization into F-actin filaments. The central actin-binding domain of Tb4, the sequence LKKTETQ (residues 17-23), is critical for this interaction. By maintaining the G-actin pool, Tb4 enables rapid cytoskeletal remodeling when cells need to migrate, divide, or change shape in response to tissue injury.

Cell Migration and Angiogenesis

Tb4 promotes both endothelial and epithelial cell migration, which are essential for wound closure and new blood vessel formation. The pro-migratory effect involves activation of integrin-linked kinase (ILK) and Akt/protein kinase B signaling. Phosphorylated Akt promotes cell survival, migration, and the expression of matrix metalloproteinases (MMPs) that facilitate tissue remodeling. Tb4 also stimulates VEGF expression, promoting angiogenesis at wound sites.

Anti-inflammatory Properties

Tb4 modulates inflammatory responses by downregulating pro-inflammatory chemokines and cytokines at wound sites. It reduces neutrophil infiltration and decreases the expression of inflammatory mediators including IL-1b, TNF-a, and MIP-2. This anti-inflammatory activity helps shift the wound environment from a destructive inflammatory phase to a constructive reparative phase.

Research Summary

Wound Healing

Malinda et al. (1999), publishing in the Journal of Investigative Dermatology, conducted the landmark study demonstrating Tb4’s wound healing properties. Topical application of Tb4 to full-thickness dermal wounds in rats accelerated wound closure by 4-6 days compared to controls. Histological analysis revealed enhanced angiogenesis, collagen deposition, and keratinocyte migration in treated wounds. This study opened a new field of Tb4 wound healing research.

Cardiac Repair

Bock-Marquette et al. (2004), in a landmark paper published in Nature, demonstrated that Tb4 promoted survival of cardiomyocytes following myocardial infarction in mice. Intraperitoneal injection of Tb4 after coronary artery ligation reduced infarct size and improved cardiac function. The mechanism involved Akt activation and subsequent inhibition of apoptotic pathways. This study initiated clinical development for cardiac applications.

Corneal Healing

Sosne et al. (2002), in Investigative Ophthalmology & Visual Science, showed that Tb4 promoted corneal epithelial wound healing and reduced inflammation in rat models of corneal injury. Phase II clinical trials conducted by RegeneRx for dry eye syndrome (RGN-259 eye drops) showed that topical Tb4 significantly improved corneal staining scores and symptom questionnaire results compared to placebo, as reported by Dunn et al. (2010) in Ophthalmology.

Neurological Recovery

Xiong et al. (2012), publishing in the Journal of Neuroscience Research, demonstrated that Tb4 treatment improved functional neurological recovery following traumatic brain injury in rats. The treated animals showed enhanced neurogenesis, oligodendrogenesis, and angiogenesis in the injured brain regions. Tb4 also promoted axonal remodeling and synaptic plasticity, contributing to improved motor and cognitive outcomes measured over 35 days post-injury.

Dosing in Published Research

TB-500 is a synthetic peptide based on a fragment of the natural protein thymosin beta-4. Although recombinant thymosin beta-4 itself has been examined in early-phase human studies, no controlled human trial has established a dose for the TB-500 fragment for the muscle, tendon or ligament uses commonly discussed. Because human dosing for TB-500 has not been defined in the published literature, specific figures circulating in vendor material are unverified and are not reported here.

Safety and Side Effects

Human safety data for TB-500 are essentially absent; the evidence base is preclinical, primarily in animal models, and controlled clinical trials have not characterized its adverse-effect profile. A specific theoretical concern follows from its proposed mechanism: TB-500 and the related thymosin beta-4 fragment promote angiogenesis and cell migration. These processes are central to wound healing, but they are also processes that tumors exploit, so a systemically administered agent with these properties carries a theoretical risk of promoting the growth or spread of an existing malignancy, a concern that has not been resolved in humans. Injectable research-chemical material is also subject to sterility, identity, and purity problems.

Current Research Status

TB-500 is not approved by the FDA or any major regulatory agency for any use. Thymosin beta-4 itself has been studied in clinical trials for indications such as dry eye and wound healing, but TB-500 as sold is not that approved-pathway product. TB-500 is prohibited in sport by the World Anti-Doping Agency. It should be regarded as an investigational compound with unestablished human efficacy and safety.

Further reading: TB-500 appears alongside GHK-Cu, BPC-157, and KPV in the KLOW peptide blend.

Frequently Asked Questions